Opinion|Videos|September 3, 2024
Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some of the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer therapies?
- How do you prepare patients who are going to receive GPRC5D therapy? What are you telling them?
Advertisement
Related to this article
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
2
FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer
3
Daily Symptom Shifts Linked to Quality of Life in Metastatic Breast Cancer
4
Surveillance, Patient Resources, and Financial Support
5